<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-11-21T04:29:03Z</responseDate><request verb="GetRecord" identifier="oai:macsphere.mcmaster.ca:11375/22024" metadataPrefix="dim">https://prod-ms-be.lib.mcmaster.ca/server/oai/request</request><GetRecord><record><header><identifier>oai:macsphere.mcmaster.ca:11375/22024</identifier><datestamp>2026-09-24T02:44:03Z</datestamp><setSpec>com_11375_271</setSpec><setSpec>col_11375_272</setSpec></header><metadata><dim:dim xmlns:dim="http://www.dspace.org/xmlns/dspace/dim" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.dspace.org/xmlns/dspace/dim http://www.dspace.org/schema/dim.xsd">
   <dim:field mdschema="dc" element="contributor" qualifier="advisor">Xie, Feng</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="advisor">Guyatt, Gordon</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="advisor">Thabane, Lehana</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="advisor">Brundage, Michael</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="author">Kovic, Bruno</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="department" lang="en_US">Health Research Methodology</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="accessioned">2017-10-03T20:12:00Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="available">2017-10-03T20:12:00Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="issued">2017-11</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">http://hdl.handle.net/11375/22024</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">https://doi.org/10.71548/10704</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="abstract" lang="en_US">Background: In oncology, progression-free survival (PFS) is a surrogate outcome&#xd;
measure and trial end point, which is increasingly being used to determine the efficacy&#xd;
and implementation in patient care of new drugs. The goal of patient-centred cancer care&#xd;
is to extend overall survival (OS) or improve health-related quality of life (HRQoL),&#xd;
however, drugs with PFS benefit are more commonly being approved for use in the&#xd;
absence of OS, when patient benefit would have to arise from improved HRQoL. The&#xd;
association between PFS and HRQoL in oncology has been poorly studied, and this&#xd;
association remains unknown. The objective of this thesis was to thoroughly evaluate the&#xd;
PFS-HRQoL association in oncology.&#xd;
Methods: We published a protocol outlining the design of a highly comprehensive&#xd;
systematic review, and a new analytical approach to optimally explore the PFS-HRQoL&#xd;
association from published oncology randomized controlled trials (RCTs). We recruited&#xd;
an international team of reviewers to conduct the systematic review across three HRQoL&#xd;
domains, and performed a quantitative analysis to find the PFS-HRQoL association in&#xd;
oncology. We examined our database of eligible RCTs for methodological issues through&#xd;
a descriptive exploration of risk of bias, to further inform on the design and conduct of&#xd;
future RCTs.&#xd;
Results: We failed to find an association between PFS and HRQoL in the absence of OS&#xd;
in oncology. Very few published oncology RCTs measure and report HRQoL&#xd;
iv&#xd;
information, and among those that do, design and conduct issues related to blinding, and&#xd;
especially attrition are common.&#xd;
Conclusion: Oncology RCTs must either be adequately powered for OS, or designed to&#xd;
properly measure HRQoL, so patients can receive treatments offering benefit in one of&#xd;
these two patient-centered outcomes, and not solely based on PFS. There is a lack of high&#xd;
quality RCTs informing on the PFS-HRQoL association, and more of these types of trials&#xd;
are needed in the future for further analysis to confirm our findings.</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="degreetype" lang="en_US">Thesis</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="degree" lang="en_US">Doctor of Philosophy (PhD)</dim:field>
   <dim:field mdschema="dc" element="language" qualifier="iso" lang="en_US">en</dim:field>
   <dim:field mdschema="dc" element="title" lang="en_US">EVALUATING THE ASSOCIATION BETWEEN PROGRESSION-FREE SURVIVAL AND HEALTH-RELATED QUALITY OF LIFE IN CANCER.</dim:field>
   <dim:field mdschema="dc" element="type" lang="en_US">Thesis</dim:field>
   <dim:field mdschema="others" element="access-status">open.access</dim:field>
</dim:dim></metadata></record></GetRecord></OAI-PMH>